{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'nominal 2-sided p-value crosses 0.05, will be considered as the \"tipping point\\' in the sense that', 'the positive conclusion drawn from the primary analysis is reversed when patients who drop out', 'are assumed to experience this fixed worsening after the discontinuation visit. After such a', 'tipping point is determined, clinical judgment will be applied as to the plausibility of the', 'assumptions underlying this tipping point. This methodology is expected to inform of what it', 'would take to overturn study conclusions based on varying assumptions about missing data. A', 'value of delta as zero will be considered equivalent to the primary analysis.', 'Page 100 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.17.', 'Appendix 17: Abbreviations', 'Table 11:', 'List of Abbreviations and Definitions of Terms', 'AChR', 'acetylcholine receptor', 'AChR Ab', 'acetylcholine receptor antibody', 'ADA', 'antidrug antibody', 'ADL', 'activities of daily living', 'AE', 'adverse event', 'AESI', 'adverse event of special interest', 'aHUS', 'atypical hemolytic uremic syndrome', 'Alexion', 'Alexion Pharmaceuticals, Inc.; the Sponsor', 'AST', 'aspartate aminotransferase', 'AZA', 'azathioprine', 'BP', 'blood pressure', 'BUN', 'blood urea nitrogen', 'C5', 'complement component 5', 'C5b-9', 'terminal complement complex', 'CFR', 'Code of Federal Regulations', 'CIOMS', 'Council for International Organizations of Medical Sciences', 'CRF', 'case report form', 'CFR', 'Code of Federal Regulations', 'C-SSRS', 'Columbia Suicide Severity Rating Scale', 'CTCAE', 'National Cancer Institute Common Terminology Criteria for Adverse', 'Events', 'CY', 'cyclophosphamide', 'CYC', 'cyclosporine', 'EC', 'Ethics Committee', 'ECG', 'electrocardiogram', 'eCRF', 'electronic case report form', 'EOS', 'End of Study', 'EQ-5D-5L', 'Euro Quality of Life', 'ET', 'Early Termination', 'EU', 'European Union', 'FDA', '(US) Food and Drug Administration', 'Page 101 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Table 11:', 'List of Abbreviations and Definitions of Terms (Continued)', 'GCP', 'Good Clinical Practice', 'gMG', 'generalized myasthenia gravis', 'GPV', 'Global Pharmacovigilance', 'HIV', 'human immunodeficiency virus', 'IB', \"Investigator's Brochure\", 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation of Technical Requirements for', 'Pharmaceuticals for Human Use', 'IEC', 'Independent Ethics Committee', 'IRB', 'Institutional Review Board', 'IRT', 'interactive response technology', 'IST', 'immunosuppressant therapy', 'IV', 'intravenous(ly)', 'IVIg', 'intravenous immunoglobulin', 'mAb', 'monoclonal antibody', 'MAC', 'membrane attack complex', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MG', 'myasthenia gravis', 'MG-ADL', 'Myasthenia Gravis Activities of Daily Living profile', 'MGC', 'Myasthenia Gravis Composite score', 'MGFA', 'Myasthenia Gravis Foundation of America', 'MGFA-PIS', 'Myasthenia Gravis Foundation of America Post-Intervention Status', 'MG-QoL15r', 'Revised Myasthenia Gravis Quality of Life 15-item scale', 'MM', 'minimal manifestation', 'MMF', 'mycophenolate mofetil', 'MMRM', 'Mixed-effects Model with Repeated Measures', 'MNAR', 'Missing Not At Random', 'MTX', 'methotrexate', 'N meningitidis', 'Neisseria meningitidis', 'NCI-CTCAE', 'National Cancer Institute Common Terminology Criteria for Adverse', 'Events', 'Neuro-QOL', 'Neurological Quality of Life', 'NMJ', 'neuromuscular junction', 'Page 102 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}